Precision BioSciences (NASDAQ:DTIL) Trading 2.6% Higher - Should You Buy?

Key Points

• Precision BioSciences' stock price increased by 2.6% to $5.06, with a significant decline in trading volume down 28% from its average.
• The company reported a quarterly loss of ($2.13) EPS, missing estimates by ($2.04), with revenue drastically lower than expected at $0.02 million against a forecast of $6.27 million.
• Insider activity included CFO John Alexander Kelly selling 14,827 shares, reducing his stake by 16.79%, while institutional investors own approximately 37.99% of the company.

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report)'s stock price rose 2.6% during mid-day trading on Friday . The stock traded as high as $5.09 and last traded at $5.06. Approximately 56,261 shares changed hands during trading, a decline of 28% from the average daily volume of 78,067 shares. The stock had previously closed at $4.93.

Precision BioSciences Stock Performance

The firm has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $4.86. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.66. The stock has a market cap of $59.66 million, a price-to-earnings ratio of -0.57 and a beta of 1.61.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($2.04). Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%.The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $6.27 million. Analysts forecast that Precision BioSciences, Inc. will post -1.23 EPS for the current fiscal year.

Insider Transactions at Precision BioSciences

In other Precision BioSciences news, CFO John Alexander Kelly sold 14,827 shares of the company's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $4.26, for a total transaction of $63,163.02. Following the transaction, the chief financial officer owned 73,485 shares of the company's stock, valued at approximately $313,046.10. This represents a 16.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Miller Financial Services LLC bought a new stake in shares of Precision BioSciences in the 1st quarter valued at $48,000. Jane Street Group LLC bought a new stake in shares of Precision BioSciences in the 4th quarter valued at $146,000. Squarepoint Ops LLC bought a new stake in shares of Precision BioSciences in the 4th quarter valued at $179,000. Bridgeway Capital Management LLC bought a new stake in shares of Precision BioSciences in the 2nd quarter valued at $260,000. Finally, Tejara Capital Ltd increased its position in shares of Precision BioSciences by 185.2% in the 1st quarter. Tejara Capital Ltd now owns 60,427 shares of the company's stock valued at $288,000 after buying an additional 39,242 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company's stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.